Clobetasone Butyrate

Summary

Clobetasone Butyrate (CHEMBL2308885) is an approved small molecule; indicated across 1 condition.

At a glance

• Status: Approved (max clinical phase 4)
• Modality: Small molecule
• Indications: 1 condition
• Clinical trials: 1
• Chemistry: 479 Da · C26H32ClFO5

Identifiers

Drug identity and classification

Field	Value
ChEMBL ID	CHEMBL2308885
Name	Clobetasone Butyrate
Type	Small molecule
Max phase	4
FDA approved	no
PubChem CID	71716069
Molecular formula	C26H32ClFO5
Molecular weight	479
InChIKey	FBRAWBYQGRLCEK-RJFLZJKCSA-N

SMILES: CCCC(=O)O[C@@]1([C@@H](C[C@H]2[C@@]1(CC(=O)[C@@]3([C@H]2CCC4=CC(=O)C=C[C@@]43C)F)C)C)C(=O)CCl

IUPAC name: [(8S,9S,10S,13S,14R,16R,17R)-17-(2-chloroacetyl)-9-fluoro-10,13,16-trimethyl-3,11-dioxo-7,8,12,14,15,16-hexahydro-6H-cyclopenta[a]phenanthren-17-yl] butanoate

Also known as: CCI 5537, CCI-5537, Clobavate, Clobet, Clobetasone butyrate, Cloburate, Cloburate-n, Eumovate, Eumovate n, GR 2/1214, GR-2/1214, Kindavate

Patent coverage: 19 distinct patent families (23 SureChEMBL compound mentions), from 1 matched compound structure(s). Mentions count patents naming the compound (not distinct inventions), so promiscuous / reference molecules inflate the mention figure — families are the dedup metric.

Targets

Targets

No target linkage available.

Bioactivity

No ChEMBL bioactivity rows at pChembl ≥ 5 (expected for biologics / antibodies).

Target pathways

No target-pathway data for this drug (no mapped target genes).

Indications & clinical

Indications

1 indication record carries no mapped disease name (EFO/MeSH-only); none shown.

Clinical trials

Total trials: 1.

Phase distribution

Phase	Trials
PHASE3	1

Top trials by phase / activity

NCT	Phase	Status	Title
NCT01567995	PHASE3	COMPLETED	Randomised, Double-blind, Placebo-controlled Study of Topical Clobetasone Butyrate 0.05% Cream in Subjects With Eczema for Two Weeks to Evaluate the Efficacy and Safety

Clinical evidence (CIViC)

No CIViC predictive evidence (expected for non-precision-medicine drugs).

Pharmacology

Pharmacogenomics

No PharmGKB pharmacogenomic data curated for this drug.

Related molecules

Related molecules

No competitor molecules sharing a primary target (ChEMBL phase ≥2 or PubChem drug-class).